Huabei Pharmaceutical Group Co., Ltd. (hereinafter referred to as Huayao group) is located in Shijiazhuang, the capital of Hebei Province. The former Huabei pharmaceutical factory was a key construction project during the first five year plan period in China. It began to be built in June 1953 and was completed and put into operation in June 1958, creating a history of large-scale production of antibiotics in China, and making important contributions to the development of human health and national pharmaceutical industry and changing the situation of lack of medicine in China. Huabei Pharmaceutical Co., Ltd. was reorganized and established in 1992 and listed on the Shanghai Stock Exchange in 1994 (Stock Name: Huabei pharmaceutical 600812). In January 1996, Huabei pharmaceutical factory was officially restructured into a wholly state-owned company - Huabei Pharmaceutical Group Co., Ltd. In June 2009, with the approval of Hebei provincial government, Jizhong energy group restructured Huayao group. Over the years, adhering to the enterprise tenet of "human health first, quality first forever", Huayao group has continued to innovate, operated steadily, gradually expanded, expanded its business scope, maintained excellent development performance, and its main economic and technical indicators have always been in the forefront of the same industry in China. By the end of 2018, Huayao group had total assets of 20.6 billion yuan, nearly 15000 employees, more than 40 subsidiaries (branches), and three national innovation platforms: National Engineering Research Center for microbial drugs, State Key Laboratory for antibody drug development, national local joint engineering laboratory for antibiotic enzyme catalysis and crystallization technology. Its main products are chemical pharmaceuticals There are nearly 1000 product specifications in the fields of modern biotechnology drugs, vitamins and nutritional health products, modern traditional Chinese medicine, biological agricultural and veterinary drugs, and the treatment fields cover anti infection, cardio cerebrovascular, nephropathy, anti-tumor and immune regulation. The process route and production layout of the main production units are designed and implemented in accordance with the current version of GMP in Europe and America and the new version of GMP in China, It has a modern pharmaceutical production platform with international leading level. In 2018, Huayao group achieved an operating revenue of 13.2 billion yuan and profits and taxes of 910 million yuan. *** Focus on the development of biological medicine industry, cultivate and develop healthy consumer goods and agricultural and veterinary medicine industry, actively build a API industry chain with competitive advantages, promote the improvement of product value, brand value and enterprise value, strive to change year by year, change greatly in three years and reshape a Xinhua medicine in five years, and strive to build a domestic leading international first-class modern pharmaceutical and health industry group.